Midwest Professional Planners LTD. Boosts Stake in Abbott Laboratories (NYSE:ABT)

Midwest Professional Planners LTD. boosted its stake in shares of Abbott Laboratories (NYSE:ABTGet Rating) by 1.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,017 shares of the healthcare product maker’s stock after buying an additional 143 shares during the period. Midwest Professional Planners LTD.’s holdings in Abbott Laboratories were worth $1,410,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the business. Morgan Stanley lifted its holdings in Abbott Laboratories by 4.5% during the second quarter. Morgan Stanley now owns 28,562,141 shares of the healthcare product maker’s stock worth $3,311,209,000 after buying an additional 1,233,152 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Abbott Laboratories by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 27,129,289 shares of the healthcare product maker’s stock valued at $3,195,052,000 after purchasing an additional 691,934 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of Abbott Laboratories by 0.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 26,698,119 shares of the healthcare product maker’s stock valued at $3,757,493,000 after purchasing an additional 82,926 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Abbott Laboratories by 4.7% during the 3rd quarter. Janus Henderson Group PLC now owns 10,026,692 shares of the healthcare product maker’s stock valued at $1,184,450,000 after purchasing an additional 451,810 shares during the last quarter. Finally, Fisher Asset Management LLC lifted its holdings in shares of Abbott Laboratories by 4.6% during the 4th quarter. Fisher Asset Management LLC now owns 8,762,768 shares of the healthcare product maker’s stock valued at $1,233,272,000 after purchasing an additional 386,089 shares during the last quarter. Institutional investors own 73.46% of the company’s stock.

ABT traded up $1.91 during midday trading on Friday, hitting $109.88. 6,159,308 shares of the company were exchanged, compared to its average volume of 5,167,185. Abbott Laboratories has a 1-year low of $104.63 and a 1-year high of $142.60. The company has a current ratio of 1.85, a quick ratio of 1.40 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $192.39 billion, a price-to-earnings ratio of 25.49, a price-to-earnings-growth ratio of 2.81 and a beta of 0.73. The company’s 50 day simple moving average is $117.37 and its 200 day simple moving average is $124.75.

Abbott Laboratories (NYSE:ABTGet Rating) last posted its earnings results on Wednesday, April 20th. The healthcare product maker reported $1.73 EPS for the quarter, beating analysts’ consensus estimates of $1.47 by $0.26. Abbott Laboratories had a return on equity of 28.72% and a net margin of 17.35%. The firm had revenue of $11.90 billion for the quarter, compared to analysts’ expectations of $11 billion. During the same period last year, the firm earned $1.32 EPS. The company’s quarterly revenue was up 13.8% on a year-over-year basis. On average, equities analysts anticipate that Abbott Laboratories will post 4.82 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, May 16th. Stockholders of record on Friday, April 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.71%. The ex-dividend date of this dividend is Wednesday, April 13th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 43.62%.

In other Abbott Laboratories news, SVP Randel William Woodgrift sold 24,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 4th. The shares were sold at an average price of $113.00, for a total value of $2,712,000.00. Following the transaction, the senior vice president now directly owns 47,854 shares of the company’s stock, valued at approximately $5,407,502. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Daniel J. Starks sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 3rd. The stock was sold at an average price of $113.22, for a total transaction of $5,661,000.00. Following the completion of the transaction, the director now directly owns 6,973,500 shares in the company, valued at $789,539,670. The disclosure for this sale can be found here. Insiders have sold a total of 81,896 shares of company stock worth $9,299,454 over the last 90 days. Insiders own 0.52% of the company’s stock.

Several analysts have recently commented on ABT shares. Morgan Stanley decreased their price objective on Abbott Laboratories from $157.00 to $151.00 and set an “overweight” rating for the company in a report on Thursday, January 27th. Wells Fargo & Company reduced their target price on Abbott Laboratories from $155.00 to $150.00 and set an “overweight” rating for the company in a research note on Friday, April 8th. Raymond James reduced their target price on Abbott Laboratories from $143.00 to $135.00 and set an “outperform” rating for the company in a research note on Thursday, April 21st. Royal Bank of Canada reduced their target price on Abbott Laboratories from $146.00 to $143.00 and set an “outperform” rating for the company in a research note on Thursday, April 21st. Finally, StockNews.com assumed coverage on Abbott Laboratories in a research note on Thursday, March 31st. They issued a “strong-buy” rating for the company. Three analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $138.83.

Abbott Laboratories Company Profile (Get Rating)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

See Also

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABTGet Rating).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.